The pending acquisition reects the potential of Mablink’s existing pipeline and proprietary PSARLink™ technology for development of additional drug conjugates. Lyon, France – October 18, 2023 – Mablink Bioscience (“Mablink”), a pre-clinical biotechnology company pioneering the development of next-generation antibody-drug conjugates (ADCs) via its PSARLink™ proprietary platform, today announced an agreement to be acquired by Eli Lilly and Company (“Lilly”).
